Clinical Snapshot
PICO Framework
| P — Population | Individuals with or at risk of gonorrhea infection |
| I — Intervention | Various diagnostic and therapeutic approaches including extended-spectrum cephalosporins, point-of-care testing, vaccination strategies, and doxycycline prophylaxis |
| C — Comparator | Current standard care and syndromic management approaches |
| O — Outcomes | Treatment efficacy, antimicrobial resistance patterns, infection control, and prevention of complications |
Bottom Line
This narrative review provides a comprehensive overview of current gonorrhea management, emphasising the continued role of extended-spectrum cephalosporins as first-line therapy while highlighting emerging challenges and opportunities. The growing threat of antimicrobial resistance necessitates culture-based susceptibility testing and antimicrobial stewardship. Promising developments include point-of-care diagnostic tests that could improve management in resource-limited settings, potential cross-protective vaccination strategies using meningococcal B vaccines, and doxycycline post-exposure prophylaxis for high-risk populations. However, the long-term implications of prophylactic antibiotic use on resistance patterns and microbiome health remain uncertain. Clinicians should maintain current evidence-based treatment protocols while staying informed about emerging resistance patterns and new therapeutic options. The review underscores the importance of comprehensive gonorrhea control programs incorporating education, accessible testing, effective treatment, and partner notification strategies.
Key Findings
P Value: Not applicable for narrative review
Effect Size: Not quantified in abstract
Primary Outcome: Extended-spectrum cephalosporins remain first-line therapy for gonorrhea
Nnt Or Sensitivity: Culture sensitivity essential for antimicrobial susceptibility testing
Confidence Interval: Not provided
Clinical Application
Recommendations appear feasible in well-resourced healthcare systems but may face challenges in resource-limited settings Highly relevant to Australian practice; aligns with current RACGP and ASHM guidelines for STI management. Point-of-care testing development would benefit remote and Indigenous communities. TGA approval would be required for new therapeutic agents mentioned. All sexually active individuals, particularly those at higher risk of STIs
Abstract
Neisseria gonorrhoeae, a Gram-negative intracellular pathogen, causes gonorrhea. Although usually sexually transmissible, it can be acquired by direct inoculation. Untreated gonococcal infections have deleterious impacts, including adverse pregnancy outcomes, ectopic pregnancy, infertility, and even blindness. Extended-spectrum cephalosporins remain the mainstay of therapy, and gonococcal culture is essential to determine susceptibility to these agents. Antimicrobial resistance is a global public health concern, and a few new agents are in the pipeline. Gonorrhea control programs rely on health education, access to diagnostic testing (where possible), effective therapy, and partner notification. Introducing inexpensive, sensitive, and specific point-of-care tests will aid antimicrobial stewardship efforts in countries using the syndromic management approach. Targeted vaccination of higher-risk populations with cross-protective outer membrane vesicle-based meningococcal B vaccines might reduce N. gonorrhoeae transmission in the future. Doxycycline postexposure prophylaxis may further reduce gonococcal incidence in the short term; however, its long-term impact on the human resistome/microbiome remains unknown.
References
- 1.Lewis, D. A. (2026). Gonorrhea. Clinical Dermatology. https://doi.org/10.1016/j.clindermatol.2025.09.006
Related Research
JMIR human factors
Japanese Health Information Technology Usability Evaluation Scale for Sexually Transmitted Infection-Related Chatbots: Development and Psychometric Validation Study
24 July 2026
The Journal of dermatological treatment
Intralesional human papillomavirus vaccination for cutaneous verrucae: a systematic review and meta-analysis of therapeutic efficacy
30 June 2026
The New Zealand medical journal
Cancer risk and screening in transgender and gender-diverse individuals on gender-affirming hormone therapy: a review article for the Australasian context
31 May 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service